Return on Assets (ROA)
since 2005
Calculation
Celgene Corp., ROA, long-term trends, calculation
| ROA | = | 100 | × | Net income (loss) attributable to Celgene1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 11.40% | = | 100 | × | 4,046) | ÷ | 35,480) |
| Dec 31, 2017 | 9.75% | = | 100 | × | 2,940) | ÷ | 30,141) |
| Dec 31, 2016 | 7.12% | = | 100 | × | 1,999) | ÷ | 28,086) |
| Dec 31, 2015 | 5.92% | = | 100 | × | 1,602) | ÷ | 27,053) |
| Dec 31, 2014 | 11.53% | = | 100 | × | 2,000) | ÷ | 17,340) |
| Dec 31, 2013 | 10.84% | = | 100 | × | 1,450) | ÷ | 13,378) |
| Dec 31, 2012 | 12.41% | = | 100 | × | 1,456) | ÷ | 11,734) |
| Dec 31, 2011 | 13.17% | = | 100 | × | 1,318) | ÷ | 10,006) |
| Dec 31, 2010 | 8.65% | = | 100 | × | 881) | ÷ | 10,177) |
| Dec 31, 2009 | 14.41% | = | 100 | × | 777) | ÷ | 5,389) |
| Dec 31, 2008 | -34.50% | = | 100 | × | (1,534) | ÷ | 4,445) |
| Dec 31, 2007 | 6.27% | = | 100 | × | 226) | ÷ | 3,611) |
| Dec 31, 2006 | 2.52% | = | 100 | × | 69) | ÷ | 2,736) |
| Dec 31, 2005 | 5.11% | = | 100 | × | 64) | ÷ | 1,247) |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The financial performance from 2005 to 2018 is characterized by an aggressive expansion of the asset base and a volatile yet generally upward trajectory in profitability. Total assets grew consistently, increasing from US$ 1,247 million in 2005 to US$ 35,480 million by 2018, representing a substantial increase in the organizational scale of operations.
- Asset Expansion and Scale
- A sustained upward trend in total assets is observed throughout the period. Significant accelerations in asset growth occurred between 2009 and 2010, and again between 2014 and 2015, during which the asset base expanded rapidly to support increased operational capacity.
- Profitability and ROA Volatility
- The Return on Assets (ROA) exhibited extreme volatility in the early years of the analyzed period. A critical decline occurred in 2008, where a net loss of US$ 1,534 million resulted in a negative ROA of -34.50%. This was followed by a sharp recovery in 2009, with ROA reaching a peak of 14.41%, signaling a rapid reversal of the previous year's losses.
- Operational Efficiency Trends
- Following the 2009 recovery, the ROA remained relatively stable, fluctuating between 8.65% and 13.17% from 2010 through 2014. A notable dip to 5.92% was observed in 2015; however, the subsequent three years showed a consistent recovery trend, with ROA ascending to 11.40% by 2018. This pattern suggests that while asset growth was rapid, the company successfully scaled its net income to maintain a healthy return on its investment base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Comparison to Competitors
Celgene Corp., ROA, long-term trends, comparison to competitors
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 11.40% | 9.58% | 12.64% | 14.06% | 5.54% | 7.36% | 8.57% | 10.00% | 7.53% | 7.00% | 20.83% | 5.22% | 33.57% |
| Dec 31, 2017 | 9.75% | 7.50% | 2.48% | 3.00% | 5.34% | -0.45% | 6.58% | 0.83% | 2.72% | 12.40% | 13.67% | 3.93% | 7.43% |
| Dec 31, 2016 | 7.12% | 9.01% | 9.95% | 13.22% | 5.64% | 7.05% | 23.70% | 11.71% | 4.11% | 4.20% | 12.84% | 4.40% | -3.87% |
| Dec 31, 2015 | 5.92% | 9.70% | 9.69% | 4.93% | 6.96% | 6.77% | 34.93% | 11.55% | 4.36% | 4.16% | 11.34% | 4.83% | -22.26% |
| Dec 31, 2014 | 11.53% | 6.44% | 7.47% | 5.94% | 7.02% | 6.43% | 34.91% | 12.45% | 12.12% | 5.40% | 8.99% | 4.42% | -31.63% |
| Dec 31, 2013 | 10.84% | 14.14% | 7.68% | 6.64% | 7.77% | 13.29% | 13.67% | 10.42% | 4.17% | 12.78% | 14.38% | 4.00% | -19.19% |
| Dec 31, 2012 | 12.41% | 19.53% | 8.00% | 5.46% | 7.26% | 11.89% | 12.20% | 8.94% | 5.81% | 7.84% | 36.06% | 4.29% | -3.88% |
| Dec 31, 2011 | 13.17% | — | 7.54% | 11.25% | 7.25% | 12.92% | 16.20% | 8.51% | 5.97% | 5.32% | -16.75% | 4.96% | 1.34% |
| Dec 31, 2010 | 8.65% | — | 10.64% | 9.98% | 8.07% | 16.35% | 25.03% | 12.96% | 0.81% | 4.23% | -9.59% | 4.85% | -43.74% |
| Dec 31, 2009 | 14.41% | — | 11.62% | 34.22% | 5.88% | 15.76% | 27.18% | 12.95% | 11.51% | 4.05% | -9.15% | 3.93% | -32.84% |
| Dec 31, 2008 | -34.50% | — | 11.51% | 17.76% | 7.53% | -7.09% | 28.65% | 15.25% | 16.54% | 7.29% | -12.34% | 4.71% | -46.90% |
| Dec 31, 2007 | 6.27% | — | 9.14% | 8.27% | 7.84% | 11.02% | 27.68% | 13.06% | 6.77% | 7.07% | -11.28% | 3.59% | -65.05% |
| Dec 31, 2006 | 2.52% | — | 8.73% | 6.20% | 8.72% | 12.13% | -29.12% | 15.67% | 9.95% | 16.84% | -17.49% | 0.79% | -22.45% |
| Dec 31, 2005 | 5.11% | — | 12.54% | 10.66% | 9.80% | 8.05% | 21.62% | 17.94% | 10.33% | 6.88% | -22.54% | 5.25% | -37.05% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Celgene Corp., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Celgene Corp. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2018 | 11.40% | 8.97% |
| Dec 31, 2017 | 9.75% | 5.28% |
| Dec 31, 2016 | 7.12% | 8.61% |
| Dec 31, 2015 | 5.92% | 8.93% |
| Dec 31, 2014 | 11.53% | 9.45% |
| Dec 31, 2013 | 10.84% | 9.46% |
| Dec 31, 2012 | 12.41% | 8.30% |
| Dec 31, 2011 | 13.17% | 7.30% |
| Dec 31, 2010 | 8.65% | 7.07% |
| Dec 31, 2009 | 14.41% | 10.02% |
| Dec 31, 2008 | -34.50% | 10.37% |
| Dec 31, 2007 | 6.27% | 8.86% |
| Dec 31, 2006 | 2.52% | 11.91% |
| Dec 31, 2005 | 5.11% | 10.42% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Celgene Corp., ROA, long-term trends, comparison to industry (health care)
| Celgene Corp. | Health Care | |
|---|---|---|
| Dec 31, 2018 | 11.40% | 7.90% |
| Dec 31, 2017 | 9.75% | 5.19% |
| Dec 31, 2016 | 7.12% | 7.31% |
| Dec 31, 2015 | 5.92% | 7.71% |
| Dec 31, 2014 | 11.53% | 8.59% |
| Dec 31, 2013 | 10.84% | 8.76% |
| Dec 31, 2012 | 12.41% | 8.09% |
| Dec 31, 2011 | 13.17% | 7.36% |
| Dec 31, 2010 | 8.65% | 7.24% |
| Dec 31, 2009 | 14.41% | 9.73% |
| Dec 31, 2008 | -34.50% | 9.50% |
| Dec 31, 2007 | 6.27% | 8.88% |
| Dec 31, 2006 | 2.52% | 10.52% |
| Dec 31, 2005 | 5.11% | 9.67% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).